3TC ACTIVE AGAINST HEPATITIS B VIRUS
3TC ACTIVE AGAINST HEPATITIS B VIRUS LAVAL, Quebec, March 13 /PRNewswire/ -- BioChem Pharma Inc.
(NASDAQ: BCHXF; Toronto, Montreal: BCH) today announced that the compound 3TC, which is currently in human clinical trials as a potential AIDS treatment, has been found active against the Hepatitis B virus.
Scientists at the 5th International Conference on Anti-viral research in Vancouver yesterday presented results on the activity of 3TC against Hepatitis B in vitro and in different animal models. In particular, 3TC has been reported to be active in primates infected with human Hepatitis B virus. Under BioChem's master license agreement with Glaxo Group Limited, Glaxo is currently conducting pre-clinical evaluation of 3TC as a potential treatment for Hepatitis B. An IND (Investigative New Drug) application for clinical trials is planned for the second quarter of this year. BioChem Pharma Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. -0- 3/13/92 /CONTACT: Francesco Bellini, president and chief executive officer of BioChem Pharma, 514-681-1744, or Luc Beauregard or Michele Roy of NATIONAL Public Relations, 514-843-7171, for BioChem Pharma/ (BCHXF) CO: BioChem Pharma Inc.; Glaxo Group Limited ST: Quebec, British Columbia IN: MTC SU:
GK-TS -- NY012 -- 7683 03/13/92 09:21 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 13, 1992|
|Previous Article:||LOUIS R. HUGHES NAMED VICE PRESIDENT OF GENERAL MOTORS|
|Next Article:||U.S. SEN. SPECTER'S AMENDMENT TO STIMULATE THE ECONOMY IS ACCEPTED INTO THE TAX BILL|